Alnylam Pharmaceuticals, Inc. (ALNY) vs Genmab A/S Sponsored ADR (GMAB)
- Alnylam Pharmaceuticals, Inc. ALNY 231.83 −0.94%
- Genmab A/S Sponsored ADR GMAB 37.00 −2.17%
Alnylam Pharmaceuticals, Inc. and Genmab A/S Sponsored ADR are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. is the larger, with a market value of $31.3B against $22.6B — 1.4× the size. Genmab A/S Sponsored ADR trades at the lower P/E: 29.1× against 39.5×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 22.3%. Genmab A/S Sponsored ADR has the higher net margin (19.1% vs 16.1%) and the higher return on invested capital (6.99% vs 0.00%). Across the 21 metrics below, Alnylam Pharmaceuticals, Inc. leads on 11 and Genmab A/S Sponsored ADR on 10.
Valuation
Profitability
| Metric | ALNY | GMAB | Biotechnology median |
|---|---|---|---|
| Gross margin | 79.65% | 93.03% | 65.16% |
| Operating margin | 20.81% | 25.95% | 0.00% |
| Net margin | 16.13% | 19.08% | 0.00% |
| Free cash flow margin | 17.07% | (153.64%) | 0.00% |
| Return on equity | 96.55% | 14.00% | (56.36%) |
| Return on assets | 15.30% | 8.30% | (48.04%) |
| Return on invested capital | 0.00% | 6.99% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack